Trending...
- Counseling Center of New Smyrna Beach Expands Affordable Mental Health Services for Volusia County
- NoviSign Sponsoring VARTECH 2025 - the B2B IT channel's #1 event
- TEAMSTERS STRIKE GREEN THUMB INDUSTRIES OVER UNFAIR LABOR PRACTICES
PITTSBURGH, Dec. 3, 2020 /PRNewswire/ -- PANTHERx® Rare Pharmacy announces that it has been selected by Alnylam Pharmaceuticals, the leading RNAi therapeutics company, as a very limited distribution pharmacy partner for new drug OXLUMO™ (lumasiran). The drug has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of primary hyperoxaluria type 1 (PH1) to lower urinary oxalate levels in pediatric and adult patients.
Primary hyperoxaluria (PH) is a group of autosomal-recessive diseases resulting from defects in different enzymes involved in glyoxylate metabolism leading to overproduction of oxalate in the liver. There are 3 types of PH: PH1, PH2, and PH3. PH1 is the most common and most severe type of PH caused by a mutation in the AGXT gene that renders the liver enzyme alanine glyoxylate aminotransferase (AGT) dysfunctional.
OXLUMO is a subcutaneously administered RNAi therapeutic that targets the messenger RNA of the hydroxyacid oxidase 1 (HAO1) gene, which encodes glycolate oxidase (GO) – the liver enzyme responsible for oxalate production and upstream of the AGT enzyme deficient in patients with PH1. By reducing the synthesis of GO, OXLUMO decreases the production of oxalate – the metabolite that directly contributes to the pathophysiology of PH1.
In the pivotal trial, ILLUMINATE-A, OXLUMO was compared against placebo in patients 6 years of age and older with PH1 and an eGFR ≥30 mL/min/1.73 m2. OXLUMO met the primary efficacy endpoint of percent reduction from baseline in 24-hour urinary oxalate excretion corrected for BSA, averaged over Months 3 through 6. Specifically, OXLUMO treatment (N=26) resulted in a mean reduction of 53.5 percent relative to placebo (N=13) (p=1.7 x 10-14), and showed a 65.4 percent mean reduction in urinary oxalate relative to baseline. The most common (≥20%) adverse reaction reported was injection site reaction. Injection site reactions occurred throughout the study period and included erythema, pain, pruritus, and swelling.
"We are honored to partner with Alnylam and provide PANTHERx's award-winning RxARECARE® services to people living with primary hyperoxaluria type 1," said Dr. Gordon Vanscoy, Chairman & CEO of PANTHERx Rare. "This rare disease medication provides a new option for patients and their families who previously had no approved pharmacologic treatment. PANTHERx is proud to serve as the link between biopharma and patients, delivering medications to the people who need them most."
More on The PennZone
For more information about the symptoms, diagnosis, and treatment of primary hyperoxaluria type 1 (PH1), please click here.
About PANTHERx® Rare Pharmacy
PANTHERx Rare Pharmacy, the largest independent and fastest growing specialty pharmacy in the United States, transforms lives by delivering medicine breakthroughs, clinical excellence, and access solutions to patients afflicted with rare and devastating conditions. Although the incidence is as common as diabetes, less than 7% of the 7,000 known rare and devastating disorders have an approved therapy. Changes in federal policy and advances in science have led to a surge in FDA orphan drug approvals, providing tremendous hope to the rare disease community.
PANTHERx was recently awarded Specialty Pharmacy of the Year by the National Association of Specialty Pharmacy (NASP) and earned the inaugural Accredited Distinction in Rare Diseases and Orphan Drugs from the Accreditation Commission for Health Care (ACHC). PANTHERx is a three-time winner of the prestigious MMIT Patient Choice Award, including the 2020 honor. PANTHERx is headquartered in Pittsburgh, Pennsylvania, licensed in all 50 states, and holds accreditations from URAC, NABP, and ACHC.
For more information, visit www.pantherxrare.com
About OXLUMOTM (lumasiran)
OXLUMO is an RNAi therapeutic targeting hydroxyacid oxidase 1 (HAO1) for the treatment of primary hyperoxaluria type 1 (PH1) to lower urinary oxalate levels in pediatric and adult patients. HAO1 encodes glycolate oxidase (GO), an enzyme upstream of the disease-causing defect in PH1. OXLUMO works by degrading HAO1 messenger RNA and reducing the synthesis of GO, which inhibits hepatic production of oxalate – the toxic metabolite responsible for the clinical manifestations of PH1. In the pivotal ILLUMINATE-A study, OXLUMO was shown to significantly reduce levels of urinary oxalate relative to placebo, with the majority of patients reaching normal or near-normal levels. Injection site reactions (ISRs) were the most common drug-related adverse reaction. In the ILLUMINATE-B pediatric Phase 3 study, OXLUMO demonstrated an efficacy and safety profile consistent to that observed in ILLUMINATE-A. OXLUMO utilizes Alnylam's Enhanced Stabilization Chemistry (ESC)-GalNAc conjugate technology designed to increase potency and durability. OXLUMO is administered via subcutaneous injection once monthly for three months, then once quarterly thereafter at a dose based on actual body weight. For patients who weigh less than 10 kg, ongoing dosing remains monthly. OXLUMO should be administered by a healthcare professional. For more information about OXLUMO, visit OXLUMO.com.
More on The PennZone
IMPORTANT SAFETY INFORMATION
Adverse Reactions
The most common adverse reaction that occurred in patients treated with OXLUMO was injection site reaction (38%). Symptoms included erythema, pain, pruritus, and swelling.
Pregnancy and Lactation
No data are available on the use of OXLUMO in pregnant women. No data are available on the presence of OXLUMO in human milk or its effects on breastfed infants or milk production. Consider the developmental and health benefits of breastfeeding along with the mother's clinical need for OXLUMO and any potential adverse effects on the breastfed child from OXLUMO or the underlying maternal condition.
For additional information about OXLUMO, please see the full Prescribing Information.
About Alnylam Pharmaceuticals
Alnylam (Nasdaq: ALNY) is leading the translation of RNA interference (RNAi) into a whole new class of innovative medicines with the potential to transform the lives of people afflicted with rare genetic, cardio-metabolic, hepatic infectious, and central nervous system (CNS)/ocular diseases. Based on Nobel Prize-winning science, RNAi therapeutics represent a powerful, clinically validated approach for the treatment of a wide range of severe and debilitating diseases. Founded in 2002, Alnylam is delivering on a bold vision to turn scientific possibility into reality, with a robust RNAi therapeutics platform. Alnylam's commercial RNAi therapeutic products are ONPATTRO® (patisiran), GIVLAARI® (givosiran), and OXLUMO™ (lumasiran). Alnylam has a deep pipeline of investigational medicines, including six product candidates that are in late-stage development. Alnylam is executing on its "Alnylam 2020" strategy of building a multi-product, commercial-stage biopharmaceutical company with a sustainable pipeline of RNAi-based medicines to address the needs of patients who have limited or inadequate treatment options. Alnylam is headquartered in Cambridge, MA. For more information about our people, science and pipeline, please visit www.alnylam.com and engage with us on Twitter at @Alnylam or on LinkedIn.
Contact: Allyson Ayoob, 855-726-8479 x 1142, [email protected]
SOURCE PANTHERx Rare Pharmacy
Related Links
http://www.pantherxrare.com
Primary hyperoxaluria (PH) is a group of autosomal-recessive diseases resulting from defects in different enzymes involved in glyoxylate metabolism leading to overproduction of oxalate in the liver. There are 3 types of PH: PH1, PH2, and PH3. PH1 is the most common and most severe type of PH caused by a mutation in the AGXT gene that renders the liver enzyme alanine glyoxylate aminotransferase (AGT) dysfunctional.
OXLUMO is a subcutaneously administered RNAi therapeutic that targets the messenger RNA of the hydroxyacid oxidase 1 (HAO1) gene, which encodes glycolate oxidase (GO) – the liver enzyme responsible for oxalate production and upstream of the AGT enzyme deficient in patients with PH1. By reducing the synthesis of GO, OXLUMO decreases the production of oxalate – the metabolite that directly contributes to the pathophysiology of PH1.
In the pivotal trial, ILLUMINATE-A, OXLUMO was compared against placebo in patients 6 years of age and older with PH1 and an eGFR ≥30 mL/min/1.73 m2. OXLUMO met the primary efficacy endpoint of percent reduction from baseline in 24-hour urinary oxalate excretion corrected for BSA, averaged over Months 3 through 6. Specifically, OXLUMO treatment (N=26) resulted in a mean reduction of 53.5 percent relative to placebo (N=13) (p=1.7 x 10-14), and showed a 65.4 percent mean reduction in urinary oxalate relative to baseline. The most common (≥20%) adverse reaction reported was injection site reaction. Injection site reactions occurred throughout the study period and included erythema, pain, pruritus, and swelling.
"We are honored to partner with Alnylam and provide PANTHERx's award-winning RxARECARE® services to people living with primary hyperoxaluria type 1," said Dr. Gordon Vanscoy, Chairman & CEO of PANTHERx Rare. "This rare disease medication provides a new option for patients and their families who previously had no approved pharmacologic treatment. PANTHERx is proud to serve as the link between biopharma and patients, delivering medications to the people who need them most."
More on The PennZone
- Geeks5g Creative Marketing: The Powerhouse Behind Business Growth
- Reported in the Journal of the American Medical Association (JAMA): Bariatric surgery offers greater weight loss, lower costs over time compared to GLP-1s, Highmark Health research demonstrates
- Pennsylvania's Potter-Tioga Region Named a Top Five Fall Destination by USA TODAY
- Agemin Unveils Breakthrough AI Model for Biometric Age Estimation, Setting New Standards in Online Child Safety
- Strategic Partnerships with Defiant Space Corp and Emtel Energy USA Powerfully Enhance Solar Tech Leader with NASA Agreements: Ascent Solar $ASTI
For more information about the symptoms, diagnosis, and treatment of primary hyperoxaluria type 1 (PH1), please click here.
About PANTHERx® Rare Pharmacy
PANTHERx Rare Pharmacy, the largest independent and fastest growing specialty pharmacy in the United States, transforms lives by delivering medicine breakthroughs, clinical excellence, and access solutions to patients afflicted with rare and devastating conditions. Although the incidence is as common as diabetes, less than 7% of the 7,000 known rare and devastating disorders have an approved therapy. Changes in federal policy and advances in science have led to a surge in FDA orphan drug approvals, providing tremendous hope to the rare disease community.
PANTHERx was recently awarded Specialty Pharmacy of the Year by the National Association of Specialty Pharmacy (NASP) and earned the inaugural Accredited Distinction in Rare Diseases and Orphan Drugs from the Accreditation Commission for Health Care (ACHC). PANTHERx is a three-time winner of the prestigious MMIT Patient Choice Award, including the 2020 honor. PANTHERx is headquartered in Pittsburgh, Pennsylvania, licensed in all 50 states, and holds accreditations from URAC, NABP, and ACHC.
For more information, visit www.pantherxrare.com
About OXLUMOTM (lumasiran)
OXLUMO is an RNAi therapeutic targeting hydroxyacid oxidase 1 (HAO1) for the treatment of primary hyperoxaluria type 1 (PH1) to lower urinary oxalate levels in pediatric and adult patients. HAO1 encodes glycolate oxidase (GO), an enzyme upstream of the disease-causing defect in PH1. OXLUMO works by degrading HAO1 messenger RNA and reducing the synthesis of GO, which inhibits hepatic production of oxalate – the toxic metabolite responsible for the clinical manifestations of PH1. In the pivotal ILLUMINATE-A study, OXLUMO was shown to significantly reduce levels of urinary oxalate relative to placebo, with the majority of patients reaching normal or near-normal levels. Injection site reactions (ISRs) were the most common drug-related adverse reaction. In the ILLUMINATE-B pediatric Phase 3 study, OXLUMO demonstrated an efficacy and safety profile consistent to that observed in ILLUMINATE-A. OXLUMO utilizes Alnylam's Enhanced Stabilization Chemistry (ESC)-GalNAc conjugate technology designed to increase potency and durability. OXLUMO is administered via subcutaneous injection once monthly for three months, then once quarterly thereafter at a dose based on actual body weight. For patients who weigh less than 10 kg, ongoing dosing remains monthly. OXLUMO should be administered by a healthcare professional. For more information about OXLUMO, visit OXLUMO.com.
More on The PennZone
- 120% Revenue Surge with Four Straight Profitable Quarters Signal a Breakout in the Multi-Billion Dollar Homebuilding Market: Innovative Designs $IVDN
- Leading Venture Capital Firms Recognize Wzzph Exchange's Technical Architecture and Security Framework as Industry Benchmark
- DivX Unveils Major DivX Software Update: Seamless Video Sharing and Customizable Playback Now Available
- New Dumpster Calculator Helps Homeowners Avoid Common $500+ Overage Fee Mistakes
- Nespolo Mechanical Helps New Mexico Families Save Thousands on Heating Costs This Fall
IMPORTANT SAFETY INFORMATION
Adverse Reactions
The most common adverse reaction that occurred in patients treated with OXLUMO was injection site reaction (38%). Symptoms included erythema, pain, pruritus, and swelling.
Pregnancy and Lactation
No data are available on the use of OXLUMO in pregnant women. No data are available on the presence of OXLUMO in human milk or its effects on breastfed infants or milk production. Consider the developmental and health benefits of breastfeeding along with the mother's clinical need for OXLUMO and any potential adverse effects on the breastfed child from OXLUMO or the underlying maternal condition.
For additional information about OXLUMO, please see the full Prescribing Information.
About Alnylam Pharmaceuticals
Alnylam (Nasdaq: ALNY) is leading the translation of RNA interference (RNAi) into a whole new class of innovative medicines with the potential to transform the lives of people afflicted with rare genetic, cardio-metabolic, hepatic infectious, and central nervous system (CNS)/ocular diseases. Based on Nobel Prize-winning science, RNAi therapeutics represent a powerful, clinically validated approach for the treatment of a wide range of severe and debilitating diseases. Founded in 2002, Alnylam is delivering on a bold vision to turn scientific possibility into reality, with a robust RNAi therapeutics platform. Alnylam's commercial RNAi therapeutic products are ONPATTRO® (patisiran), GIVLAARI® (givosiran), and OXLUMO™ (lumasiran). Alnylam has a deep pipeline of investigational medicines, including six product candidates that are in late-stage development. Alnylam is executing on its "Alnylam 2020" strategy of building a multi-product, commercial-stage biopharmaceutical company with a sustainable pipeline of RNAi-based medicines to address the needs of patients who have limited or inadequate treatment options. Alnylam is headquartered in Cambridge, MA. For more information about our people, science and pipeline, please visit www.alnylam.com and engage with us on Twitter at @Alnylam or on LinkedIn.
Contact: Allyson Ayoob, 855-726-8479 x 1142, [email protected]
SOURCE PANTHERx Rare Pharmacy
Related Links
http://www.pantherxrare.com
Filed Under: Business
0 Comments
Latest on The PennZone
- Only 3 Weeks Left till the Start of the OpenSSL Conference 2025
- ENTOUCH Completes $50 million Funding Round
- Teaming Agreement with Emtel Energy USA to Advance Thin-Film PV Energy Storage Capabilities; NASA agreements for Solar Space Tech; Ascent Solar $ASTI
- Nebuvex Acknowledges Platform "Too Secure" for Anonymous Traders; Institutional Investors Disagree
- From Tokyo to Berlin: FreeTo.Chat Unites Cultures with the World's First Confession VRX — EmojiStream™
- Promising New Preclinical Therapy Offers Hope in the Development of Precision Medicine Treatments for Aggressive Cancers
- AZETHIO Launches Multi-Million Dollar User Protection Initiative Following Unprecedented Platform Growth
- Matecrypt Observes South American Cryptocurrency Adoption Surge Amid Economic Shifts
- Assent Uncovers Over 695 Unique PFAS Across Global Supply Chains as Regulations Increase
- Cryptocurrency Quarterly Trading Volume Surpasses $15 Trillion Record High as BrazilNex Acknowledges Industry 'Growing Pains' Amid Market Speculation
- AHRFD Initiates Legal Proceedings Against Anwalt.de for Publishing Defamatory and False Content
- New Analysis Reveals the Complex Forces Driving the 'Great Human Reshuffle'
- Elevate Unveils GroundComm X30 at 2025 International GSE Expo in Las Vegas
- NEW power supply release from Kepco Dynatronix - HSP Advanced
- St. Augustine Honors Hispanic Heritage Month
- Vesica Health Receives AUA Guideline Inclusion
- Steward's Plumbing Sponsors the 2025 Samson Challenge, Bringing Community, Fitness, and Fun Together in Albuquerque
- What Has The Thought Processes of Religion Become: Thou Shall Not Kill
- Berger Montague Investigates Hims & Hers Health Inc. (NYSE: HIMS) Board of Directors for Potential Breaches of Fiduciary Duties
- WorldUpstart Expands Global Footprint to Bring Healthcare Innovation to the U.S. Market